Med-X Partners with Anasac Ambiental for Nature-Cide Product Distribution in South America

NASDAQ Here We Come. Meet MXRX.

We’re planning a direct listing on the Nasdaq, and we’ve already reserved the ticker symbol "MXRX.” This is a rare opportunity to invest before it happens.

Sign Up For Company Updates

Your Email
Submission received! Check your inbox for the Med-X updates.

Exclusive Distributor to Drive International Growth in Chile, Argentina, Peru and Colombia

LOS ANGELES – January 9, 2025 -- Med-X, Inc., a leading innovator of all-natural green scene solutions addressing the pest control, health and wellness markets, today announced an international distribution agreement with Anasac Ambiental S.A., providing exclusive Nature-Cide distribution rights in Chile, Argentina, Peru and Colombia. 

Anasac, a Chilean company, has provided sustainable and innovative solutions that promote development and wellbeing in areas including crop protection, seeds, veterinary care, home & garden, environmental health, pets, hygiene & disinfection, and medication for over 75 years. Anasac has a presence in 19 counties worldwide with over 1,500 products. The company’s subsidiary, Anasac Ambiental, produces and markets solutions for pets, gardens and green areas, as well as urban and agro-industrial pest control. 

Per the terms of the agreement, Anasac Ambiental will serve as the exclusive distributor of the Nature-Cide portfolio of indoor and outdoor pest control solutions to a wide variety of professional pest management customers in Chile, Argentina, Peru and Colombia.

Matthew Mills, Chief Executive Officer of Med-X, commented: "This new international distribution agreement marks our entrance into the South American market with Anasac, a well-known Chilean leader in agriculture and pest control.  Anasac Ambiental will help to introduce our flagship Nature-Cide product portfolio into Chile and neighboring countries Argentina, Peru and Colombia.

“As a major agricultural region with significant pest pressure, the need for Nature-Cide in home, agricultural and commercial applications has never been stronger. We look forward to working closely with the Anasac team to provide the Nature-Cide product portfolio as a best-in-class option to pest control operators seeking sustainable natural and effective solutions in these exciting new international markets," concluded Mills.

Francisco Di Silvestre, General Manager of Anasac Ambiental, added: “We chose to partner with Med-X due to Nature-Cide's wide range of environmentally friendly and effective solutions, providing critical solutions to the major issues that pest control operators face every day. We believe our base of customers will benefit from these cost-effective high-quality, all-natural products, and improve their pest management programs. At Anasac, we are committed to a sustainable future for pest control and look forward to the opportunity to bring Nature-Cide products to a wide variety of our customers.”

About Med-X, Inc.

Med-X, Inc. is a leading innovator of biological pest control solutions addressing both consumer and professional markets globally. Nature-Cide - the Company's flagship product line - is a safer, all-natural alternative to conventional chemical products, formulated to kill or repel a wide variety of pests. Med-X's comprehensive go-to-market strategy includes leveraging strategic partnerships alongside an integrated e-commerce, brick and mortar and on-site services presence in key markets. For more information, please visit our website at www.medx-rx.com.

Disclaimer and Forward-Looking Statements

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Any offers, solicitations or offers to buy, or any sale of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"). This announcement is being issued in accordance with Rule 135 of the Securities Act. This press release may contain forward-looking statements regarding projected business performance, operating results, financial condition, and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The Company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the Company incurring operating losses and experiencing unexpected material adverse events. 

Investor Relations Contact

Lucas Zimmerman 

Managing Director

MZ Group - MZ North America

+1 (262) 357-2918

MXRX@mzgroup.us  

www.mzgroup.us   

FAQs

Where can I find more information on Med-X?

You can review all of Med-X’s SEC Filings, including the offering circular for the Regulation A+ offering, here.

What is the offering Price?

The offering price is [$X] per [security type] and the minimum investment amount for this round is [Min Investment Amount].

How and when can I access the subscription document and invest?

Click “Invest Now” anywhere on this site, or follow this link [insert link here]. You will be directed to view the subscription agreement and complete an investment. Payment is accepted via [insert payment options].

What payment options are available?

Investors can purchase shares via credit card, bank-to-bank payments, or express wires (reconciled in real-time). An administrative fee of $[  ] will be applied to all investments. (if applicable).

Do I need to be an accredited investor?

This offering is open to both accredited and non-accredited investors. If you are a non-accredited investor, please note that you cannot invest more than 10% of the greater of your annual income or net worth.

What is an accredited investor? 

According to the SEC, an individual accredited investor can be defined as the following:  

An accredited investor, in the context of a natural person, includes anyone who: 

  • earned income that exceeded $200,000 (or $300,000 together with a spouse or spousal equivalent) in each of the prior two years, and reasonably expects the same for the current year, OR 
  • has a net worth over $1 million, either alone or together with a spouse or spousal equivalent (excluding the value of the person’s primary residence), OR 
  • holds in good standing a Series 7, 65 or 82 license. 

Additionally, an accredited investor as an entity can be defined as the following: 

  1. A trust is considered to be an accredited investor if its assets exceed $5 million, it is not created to purchase the securities and it is directed by a sophisticated person; or 
  1. An entity is an accredited investor if its investment exceeds $5 million and it is not created to purchase securities. 
  1. An entity in which all equity owners are accredited investors. 
Why did my payment get rejected? What can I do to resolve this?

If your credit card payment was declined, please call your credit card provider to pre-authorize the transaction. Additionally, if your bank-to-bank transfer via ACH has failed, it is recommended that you contact your bank for more information.

How can I change the email address associated with my account?

To change your email address, please navigate to the top-right corner of your Dashboard. Within your profile settings, you can change the email address associated with your account. If you would like to merge investments to a pre-existing account, under a different email address, please contact info@dealmaker.tech for assistance. Please specify the applicable email addresses to be changed. For investor security, you will be asked to verify that you have access to the applicable accounts.

How can I invest as a trust or corporation?

You can specify whether you are investing as an individual, or as a corporation/trust/custodial. Upon selecting any of the non-individual options, you will be prompted to enter relevant information and populate your subscription agreement accordingly.

What happens after I complete the online investment process?

1) Funding Processed:  

Your investment funding status will update upon receipt of your funds. If paying by bank-to-bank transfer, your payment will initially appear as pending, and will either clear or fail within five business days. If paying by wire domestically, your wire should be reconciled within one business day. International wires vary. Once funds are received, it can take approximately [1-2 weeks] *customize per issuer to process your investment completely. 

2) Identity Processed: 

In some instances, we may reach out to you requesting additional information in order to verify your identity & finish processing your investment, which may increase the overall processing time. 

3) Subscription Confirmation: 

Once your investment has been fully processed and confirmed, you will receive a notification when your subscription agreement has been accepted.Subsequently, you will receive a digital confirmation of the security holdings.If a [number of weeks] pass by and you do not receive any information from us, please email us at [company email address] We may still require additional information. We recommend you check your spam folder first for any email communications! 

Will I receive a paper share certificate?

Please note that if your securities are being distributed through the DealMaker platform, you will receive a digital certificate or DRS statement from the issuer’s transfer agent, uploaded to your investment portal. No paper share certificates are distributed via DealMaker.  

For further information regarding DRS statement distribution, please contact our investor support team at: [insert email address/phone number] or our transfer agent at: [insert transfer agent contact].  

When will this raise end?

Currently, the deadline for the offering is [INSERT DATE]. We may close the offering earlier than the deadline in the offering materials, for example, if we reach the target offering amount prior to the deadline.

I would like to speak to someone about my investment, who can I contact? 

For more information regarding your investment in this offering, please contact our investor support team at: investorrelations@medx-rx.com

I haven’t found the answer to my question. Where can I look next? 

You can search the DealMaker knowledge base for more information here, or contact investor support at investorrelations@medx-rx.com

Can I transfer my shares? 

Yes. Securities sold in a Regulation A+ offering are not considered “restricted securities” under Securities Act Rule 144. As a result, sales of securities by persons who are not affiliates of the issuer are not subject to any transfer restrictions.

Investors need to check with a brokerage account representative to determine whether their provider will allow for the securities to be (i) directly deposited to a brokerage account or (ii) transferred into such account at a later day. The policies may vary between different providers. 

Get our investor deck for an in-depth look at our potential in the $17.6B global pesticide market.

Submission received! Check your inbox for the Med-X updates.